You'd think! |
Three positive RNS today, should be a decent day for GSK 👊 |
Company RNS out to confirm the same .. |
Looking at the volume and 3.7% increase in the price yesterday in the US listed stock, the Americans seem confident |
Wasn't aware but definitely positive. The Delaware judge went against the flow of legal opinion to date and the fact that they allowing the appeal to be heard implies they know this. |
Surprised by the lack of comment here, on ADVFN, regarding this... |
about time it turned around then |
GSK unperformed for 2 decades . Pleased to be out of it . |
GSK have traded sideways for 20-25 years now, and on a small PE of 16..
In contrast AZN have gone from 20 quid to 130 and trading on a PE of 41
IF the Zantac wins stack up, it does make an awkward precedent for other judges to rule against us, we could see 1800 again by year end for starters, with plenty of headroom..
Nice to see HLN up from 275-375 for free too, a small dividend there but it is ramping up slowly as the debt winds off.. :o) |
As a recent buyer of GSK I personally am holding for the longer term as I can easily see these doubling as Zantac litigation slowly fades and the promising new pipeline comes to market. There is no doubt in my mind that these are trading far too low |
But we all lost loads when GSK fell two quid from 18.10 to 15 pounds! |
No, not all out .... I bought 5603 additional shares at 1509.3p on 31 July. Received the 15p dividend en route, and just sold 5603. This was 20% of my holding. |
Hi can I ask if you are all out or just trading portion? |
OUT @ 1606p .... ;0) |
 This is better:
GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner.
The pharmaceuticals developer said it has received 'breakthrough therapy designation' from the US Food and Drug Administration (FDA) for the antibody-drug conjugate to treat relapsed or refractory extensive-stage small-cell lung cancer, an aggressive form of lung cancer.
Breakthrough therapy designation is given for drugs that have the potential to help treat serious conditions and where preliminary clinical evidence may indicate substantial improvement over currently available therapy.
The drug, which currently goes by the name HS-20093 or the code GSK5764227, has shown promising early clinical evidence, the company said, in trials in China.
It is being developed by Chinese biopharmaceutical company Hansoh Pharma for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumours.
It is in multiple phase I and II clinical trials in China, with GSK's global Phase I trials for GSK5764227 set to begin in the second half of this year.
GSK said results from the early-stage clinical trial will be presented at the 2024 World Conference on Lung Cancer taking place in early September and it plans to begin global phase-two trials in the second half of the year.
GSK acquired exclusive worldwide rights for GSK5764227 from Hansoh earlier this year. |
1.29 USD = GBP 1 not helpful .... ;0) |
Jemperli (Ph3 RUBY trial approval
Jemperli has been given August 23 as a prescription drug user fee act action date for the FDA decision.
(Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases) |
The rising pound and a drop in the fuse is not helping GSK either. |
GSK's Florida state court win is a positive twist in its Zantac litigation saga but concerns continue to cloud the business, AJ Bell Investment director Russ Mould says in a market comment. "The Zantac cloud is overshadowing the progress CEO Emma Walmsley has made in turning around the business and, notwithstanding the good news from Florida, this might continue to prove the case for some time to come," he says. The British pharma giant's continuing legal battle over links between Zantac and cancer remains an issue for the business due to its high case volume, the analyst says. GSK's hope that a similar case dismissal in late 2022 would mark the beginning of the end hasn't materialized yet, he says. The Florida ruling contrasts a Delaware court decision earlier this year that weighs more significantly on GSK, given it accounts for the majority of outstanding cases, Mould says. |
"precedence", abdullla - a good point, though |
The remaining cases ought to be dismissed under the laws of presidence |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
